Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Ho

Showing results (101-110 of 143) with videos related to

Pageof 15
Sort By:
Journal of Cancer|October 6, 2010
Mesothelin as a potential therapeutic target in human cholangiocarcinomaLiping Yu, Mingqian Feng, Heungnam Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2013
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinomaMingqian Feng, Wei Gao, Ruoqi Wang, et al.
Molecular Cancer Therapeutics|February 2, 2013
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surfaceZhewei Tang, Mingqian Feng, Wei Gao, et al.
Journal of Translational Medicine|August 5, 2020
32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinomaXiaoyu Liu, Fang Gao, Longwei Jiang, et al.
Bioconjugate Chemistry|August 22, 2024
Sortase-Mediated Site-Specific Conjugation to Prepare Fluorine-18-Labeled NanobodiesFalguni Basuli, Jianfeng Shi, Eric Lindberg, et al.
Molecular Cancer Therapeutics|May 2, 2022
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid TumorsSakshi Tomar, Jingli Zhang, Manakamana Khanal, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid TumorsMingyu Huo, Dan Li, Nan Li, et al.
Nature Reviews. Cancer|May 13, 2024
Cancer therapy with antibodiesSuman Paul, Maximilian F Konig, Drew M Pardoll, et al.
Nanomedicine (London, England)|May 2, 2015
Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxelHirofumi Hanaoka, Takahito Nakajima, Kazuhide Sato, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 20, 2019
<i>In Vitro</i> Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and PotencyRose M Berman, Olivia J Kelada, Nicholas T Gutsche, et al.
Pageof 15

Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
Journal of Cancer|October 6, 2010
Mesothelin as a potential therapeutic target in human cholangiocarcinomaLiping Yu, Mingqian Feng, Heungnam Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2013
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinomaMingqian Feng, Wei Gao, Ruoqi Wang, et al.
Molecular Cancer Therapeutics|February 2, 2013
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surfaceZhewei Tang, Mingqian Feng, Wei Gao, et al.
Journal of Translational Medicine|August 5, 2020
32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinomaXiaoyu Liu, Fang Gao, Longwei Jiang, et al.
Bioconjugate Chemistry|August 22, 2024
Sortase-Mediated Site-Specific Conjugation to Prepare Fluorine-18-Labeled NanobodiesFalguni Basuli, Jianfeng Shi, Eric Lindberg, et al.
Molecular Cancer Therapeutics|May 2, 2022
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid TumorsSakshi Tomar, Jingli Zhang, Manakamana Khanal, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid TumorsMingyu Huo, Dan Li, Nan Li, et al.
Nature Reviews. Cancer|May 13, 2024
Cancer therapy with antibodiesSuman Paul, Maximilian F Konig, Drew M Pardoll, et al.
Nanomedicine (London, England)|May 2, 2015
Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxelHirofumi Hanaoka, Takahito Nakajima, Kazuhide Sato, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 20, 2019
<i>In Vitro</i> Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and PotencyRose M Berman, Olivia J Kelada, Nicholas T Gutsche, et al.
Pageof 15